NCCN Guidelines® Insights - Breast Cancer, Version 1.2016

These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer. In the most recent version of these guidelines, the NCCN Breast Cancer Panel included a new section on the principles of preoperative systemic therapy. In addition, based on new evidence, the panel updated systemic therapy recommendations for women with hormone receptor–positive breast cancer in the adjuvant and metastatic disease settings and for patients with HER2-positive metastatic breast cancer. This report summarizes these recent updates and discusses the rationale behind them.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Breast Cancer
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer
Additional information
Supporters: 

Supported by an educational grant from Eisai; a contribution from Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech BioOncology, Merck, Novartis Oncology, Novocure; and by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/21/2015
Course expires: 
12/21/2016
Cost:
$0.00

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

EDITOR:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE PLANNERS:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.

Ann Gianola, MA, Senior Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
William J. Gradishar, MD, Panel Chair, has disclosed that he has no relevant financial relationships.

Benjamin O. Anderson, MD, Panel Vice-Chair, has disclosed that he has no relevant financial relationships.

Sarah L. Blair, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Amy Cyr, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Anthony D. Elias, MD, Panel Member, has disclosed that he receives grant/research support from Eisai Inc., Medivation, Inc., Astellas US LLC, ZIOPHARM Oncology, Inc., ImClone Systems Incorporated, Genentech, Inc., Incyte Corporation, and Johnson & Johnson Services, Inc.; has equity interest/stock options in Pfizer Inc., Genentech, Inc., and Bristol-Myers Squibb Company; and is a scientific advisor for Genentech, Inc.

Andres Forero, MD, Panel Member, had disclosed that he receives grant/research support from Genentech/Roche, Novartis Pharmaceuticals Corporation, Daiichi Sankyo, Inc., Seattle Genetics, Inc., TRACON Pharmaceuticals, Inc., MedImmune, LLC, Incyte Corporation, Celgene Corporation, AbbVie Inc., GlaxoSmithKline plc, and Pfizer Inc.

Matthew Goetz, MD, Panel Member, has disclosed that he is a scientific advisor trial for Lilly Oncology.

Lori J. Goldstein, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Clifford A. Hudis, MD, Panel Member, has disclosed that he receives consulting fees and honoraria from Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Roche Laboratories, Inc.; and serves as a scientific advisor for Pfizer Inc. and Roche Laboratories, Inc.

Steven J. Isakoff, MD, PhD, Panel Member, has disclosed that he receives grant/research support from AbbVie Inc., Genentech, Inc., and PharmaMar; and receives consulting fees from Merrimack Pharmaceuticals, Inc., AbbVie Inc., and Myriad Genetics, Inc.

Kilian E. Salerno, MD, Panel Member, has disclosed that he has no relevant financial relationships.

Karen Lisa Smith, MD, MPH, Panel Member, has disclosed that she has equity interest/stock options in AbbVie Inc., Abbott Laboratories, Express Scripts, and Hospira, Inc.

Hatem Soliman, MD, Panel Member, has disclosed that he receives consulting fees from Celgene Corporation.

George Somlo, MD, Panel Member, has disclosed that he receives grant/research support from Genentech, Inc., Agendia, and AstraZeneca Pharmaceuticals LP; is a scientific advisor for Pfizer Inc., Genentech, Inc., and Agendia; and is a member of a speakers’ bureau for Takeda.

Melinda Telli, MD, Panel Member, has disclosed that she receives other financial benefit from Vertex Pharmaceuticals Incorporated.

Dorothy A. Shead, MS, Director, Patient & Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-15-011-H01-P

All clinicians completing this activity will be issued a certificate of participation.

Release date: December 21, 2015
Expiration date: December 21, 2016

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing